Technology | October 10, 2014

Preventice Adds Three-in-one Switchability to BodyGuardian Remote Monitoring System

Enhancement delivers mobile cardiac telemetry, event monitoring and Holter technology — in one easy-to-use system

Preventice Three-in-one Switchability BodyGuardian Remote Monitoring System

Preventice Three-in-one Switchability BodyGuardian Remote Monitoring System

October 10, 2014 — Preventice Inc. announced improvements to its BodyGuardian Remote Monitoring System that have the potential to simplify the remote monitoring experience for patients and contribute to a more efficient care delivery process when transitioning between monitoring needs for individual patients. At the same time, the improved BodyGuardian could simplify administrative billing and service operations for health care providers. The BodyGuardian product enhancements make these improvements possible by combining three essential monitoring technologies — mobile cardiac telemetry, event monitoring and Holter monitoring — in one easy-to-use device.

“For years, monitoring patients at varying stages of cardiac disease has necessitated the use of multiple monitoring devices, which can create confusion and anxiety for the patient—not to mention a prolonged monitoring experience, additional training for clinicians and patients, and billing complexity,” said Bryan Claseman, vice president of marketing for Preventice. “The BodyGuardian addresses these issues by combining the three most common types of monitoring technologies into one device.”

Cardiac patients are typically monitored in one of three ways, and oftentimes, healthcare providers will need to switch between the following monitoring devices to get a clear and correct diagnosis: 1) mobile cardiac telemetry, which collects a broader base of physiological data in near real time over a longer time period; 2) event monitoring, wherein rhythms are tracked in conjunction with a specific cardiac event such as bradycardia, and 3) Holter monitoring, which tracks cardiac rhythms in near real time for short periods. The BodyGuardian now enables clinicians to switch between these monitoring modes to diagnose varying patient needs, with one easy-to-use device.

Diagnosing a cardiac condition can take time and may require multiple diagnostic approaches,” said Peter Brady, medical director, Electrocardiographic, Heart Rhythm and Physiological Monitoring Laboratory, at the Mayo Clinic. “Transitioning between different monitoring modes would normally add time and complexity to this process for both patients and providers. Using a single device with three-in-one switchability has the potential to alleviate this, allowing health care facilities to deliver a more seamless and effective patient care experience.”

The BodyGuardian can potentially lead to a faster diagnosis and, ultimately, treatment than traditional devices because health care providers do not have to physically exchange devices with their monitoring facility, which can delay the delivery of reports about a patient’s condition until after the device is returned and reports are downloaded. Instead, the BodyGuardian allows the provider to move between monitoring approaches with the flip of a virtual switch.

“Delivering continuity of care and a safe, seamless patient experience is of utmost importance to health care providers today,” said Jon Otterstatter, president and founder of Preventice. “As health reform demands a greater focus on quality outcomes and reducing costs, providers will turn to technology like remote monitoring to diagnose and treat more patients in ways that use time, money and staff resources efficiently and effectively.”

Developed in collaboration with Mayo Clinic, the BodyGuardian uses sophisticated algorithms to support remote monitoring for individuals with cardiac arrhythmias. The BodyGuardian is approved for use in detecting and monitoring non-lethal cardiac arrhythmias for ambulatory patients.

For more information:

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
PURE study may cause revision of fat intake guidelines for cardiology.
Feature | ESC| September 07, 2017
September 7, 2017 — Researchers at the European Society of Cardiology (ESC) Congress called for a reconsideration of
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Overlay Init